Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference
22 Novembro 2023 - 9:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
with an emphasis on treatments for viral infections, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will participate in a fireside chat at Evercore ISI
HealthCONx Conference on November 29, 2023 at 7:55 a.m. ET in
Miami, FL.
A live webcast of the event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. A replay of the webcast will be
available following the presentation and will be archived for at
least 30 days.
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs with an emphasis on treatments for viral infections.
Enanta’s research and development programs include clinical
candidates for the following disease targets: respiratory syncytial
virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV).
A portion of Enanta’s royalties from hepatitis C virus (HCV)
products developed under its collaboration with AbbVie contribute
to the ongoing funding of Enanta’s operations. Glecaprevir, a
protease inhibitor discovered by Enanta, is part of one of the
leading treatment regimens for curing chronic HCV infection and is
sold by AbbVie in numerous countries under the tradenames MAVYRET®
(U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please
visit www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231122012068/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024